Torrent Pharma
Market cap ₹1.84 L Cr
- P/E
- 77.51
- Day range
- ₹4,837.50 – ₹4,959.50
- 52-week range
- ₹3,480.60 – ₹5,250.00
- Volume
- 3.97 L
- Open
- ₹4,931.00
- Prev close
- ₹4,965.50
Key metrics
- P/E (TTM)
- 78.7
- EPS (TTM)
- ₹62.60
- ROE (FY26)
- 26.8%
- ROCE (latest year)
- 15%
- Dividend yield
- 0.77%
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
Bars in ₹ crore (a loss shows red); line is operating margin
- Revenue
- Net profit
- Operating margin
Who owns the company
Shareholding as of Jul 2026
- Promoter
- FII
- DII
- Public
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); line is debt-to-equity
- Equity
- Debt
- Debt / equity
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 |
| Expenses | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 | 2,219 | 2,215 | 2,841 | 3,257 |
| Operating Profit | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 | 1,664 |
| OPM % | 31% | 32% | 32% | 32% | 32% | 33% | 33% | 32% | 33% | 33% | 32% | 34% |
| Other Income | 26 | 55 | 31 | 24 | -16 | 33 | -42 | -37 | -40 | -23 | -83 | -33 |
| Interest | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 | 45 | 236 | 305 |
| Depreciation | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 | 206 | 508 | 593 |
| Profit before tax | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 |
| Tax % | 31% | 30% | 29% | 30% | 31% | 27% | 25% | 26% | 25% | 22% | 31% | 23% |
| Net Profit | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 |
| EPS in Rs | ₹11.41 | ₹13.09 | ₹13.27 | ₹13.50 | ₹13.38 | ₹14.86 | ₹14.71 | ₹16.19 | ₹17.46 | ₹18.76 | ₹10.76 | ₹16.72 |
From company filings, updated 15 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.
Working-capital cycle
+10 days since Mar 2021
-118 days since Mar 2021
-97 days since Mar 2021
-11 days since Mar 2021
-21 days since Mar 2021
Strengths, risks & growth
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. [1] It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses. [2]
Strengths
- Company is expected to give good quarter
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
- Company has been maintaining a healthy dividend payout of 57.8%
Risks
- Stock is trading at 20.0 times its book value
- Promoter holding has decreased over last quarter: -7.53%
- The company has delivered a poor sales growth of 11.8% over past five years.
- Company might be capitalizing the interest cost
Compounded Sales Growth
- 10 Years
- +8%
- 5 Years
- +12%
- 3 Years
- +13%
- TTM
- +33%
Compounded Profit Growth
- 10 Years
- +2%
- 5 Years
- +12%
- 3 Years
- +22%
- TTM
- +10%
Stock Price CAGR
- 10 Years
- +20%
- 5 Years
- +26%
- 3 Years
- +38%
- 1 Year
- +41%
Return on Equity
- 10 Years
- +22%
- 5 Years
- +24%
- 3 Years
- +26%
- Last Year
- +27%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 68.31% | 68.31% | 68.31% | 60.78% | -7.53 pp |
| FII | 16.13% | 16.18% | 15.44% | 17.97% | +2.53 pp |
| DII | 9.05% | 8.96% | 9.73% | 12.77% | +3.04 pp |
| Government | 0.10% | 0.00% | 0.10% | 0.09% | -0.01 pp |
| Public | 6.41% | 6.55% | 6.42% | 8.39% | +1.97 pp |
Filed with NSE for Jul 2026: promoters 60.78%, public 39.22% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 8.27% (+3.33 pp)- Promoters60.8%
- Foreign institutions18.0%
- Mutual funds8.3%
- Insurance2.0%
- Other domestic institutions2.6%
- Retail4.4%
- Others4.0%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Large Cap Fund | 0.86% | 4.04% | +0.27 pp |
| Kotak Mid Cap Fund | 0.47% | 1.23% | +1.23 pp |
| Axis Small Cap Fund | 0.40% | 2.39% | +2.39 pp |
| Axis Large Cap Fund | 0.21% | 1.26% | +0.21 pp |
| UTI Flexi Cap Fund | 0.19% | 1.43% | +0.03 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 248 daily sessions to 11 Sept 2026.
Risk
- Volatility (1Y)
- 21.8%
- Downside volatility
- 20.3%
- Worst 5% of days
- 2.2%
- Average of that tail
- 2.8%
- Max drawdown (1Y)
- 10.3%
- Below its peak
- 3.1%
Against the market
- Beta vs Nifty 50
- 0.25
- Correlation
- 0.15
- Relative strength (3M)
- +12.2%
- ATR (14)
- 2.1%
Return
- Return 1M
- +1.0%
- Return 3M
- +10.2%
- Return 6M
- +12.1%
- Return 1Y
- —
- vs 200-day average
- +13.9%
Momentum
- RSI (14)
- 52.2
- MACD histogram
- -5.42
- Stochastic %K
- 58.6
- ADX (14)
- 12.6
- +DI / −DI
- 16.8 / 16.0
- Money flow index
- 47.6
Participation
- Delivery (20d avg)
- 60.2%
- vs its 60-day baseline
- +0.8 pts
- Volume vs 20-day
- -0.1σ
- Close vs day's VWAP
- +0.4%
- 52-week position
- 90 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Jun 2026.
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹9.00
Dividend - Rs 9 Per Share
29 May 2026ex-date - dividend₹29.00
Interim Dividend - Rs 29 Per Share
18 Feb 2026ex-date - dividend₹6.00
Dividend - Rs 6 Per Share
20 Jun 2025ex-date - dividend₹26.00
Interim Dividend - Rs 26 Per Sh
31 Jan 2025ex-date - dividend₹6.00
Dividend - Rs 6 Per Share
21 Jun 2024ex-date - dividend₹22.00
Interim Dividend - Rs 22 Per Share
12 Feb 2024ex-date - dividend₹8.00
Dividend - Rs 8 Per Share
23 Jun 2023ex-date - dividend₹14.00
Interim Dividend - Rs 14 Per Share
3 Feb 2023ex-date - bonusNot available — not reported in this filing
Bonus 1:1
8 Jul 2022ex-date - dividend₹25.00
Interim Dividend - Rs 25 Per Share
2 Feb 2022ex-date - dividend₹15.00
Dividend - Rs 15 Per Share
17 Jun 2021ex-date - dividend₹20.00
Interim Dividend - Rs 20 Per Share
15 Feb 2021ex-date - dividend₹17.00
Interim Dividend - Rs 17 Per Share Special Dividend - Rs 15 Per Share
18 Mar 2020ex-date - dividend₹4.00
Dividend Rs 4 Per Share
13 Jun 2019ex-date - dividend₹13.00
Interim Dividend - Rs 13 Per Share
6 Feb 2019ex-date - dividend₹5.00
Dividend- Rs 5 Per Share
18 Jun 2018ex-date - dividend₹9.00
Interim Dividend Rs 9/- Per Share (Purpose Revised)
15 Feb 2018ex-date - dividend₹4.00
Dividend - Rs 4/- Per Share
19 Jun 2017ex-date - dividend₹10.00
Interim Dividend Rs 10/- Per Share (Purpose Revised)
10 Feb 2017ex-date - dividend₹15.00
Interim Dividend - Rs 15/- Per Share (Purpose Revised)
16 Mar 2016ex-date
Company announcements
Intimation of Schedule of Investor Meets
Newspaper advertisement in respect of special window for transfer and dematerialisation of physical shares
Outcome of Postal Ballot
Scrutinizer's Report on the Postal Ballot
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
ESG Rating
Newspaper Advertisement for completion of dispatch of Postal Ballot Notice
Notice of Postal Ballot
Transcript of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2026
Intimation of Cessation of Director of the Company
Recording Link of Analyst call - Q1 Results
Change in Senior Management Personnel
Outcome of Board Meeting dated 30-Jul-26
Results for quarter ended 30-Jun-26
Appointment of Shanti Ekambaram as an Independent Director of the Company
Filed with BSE (scrip 500420); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Jul 2026Transcript
- May 2026TranscriptRecording
- Feb 2026TranscriptRecording
- Nov 2025TranscriptSlidesRecording
- Jul 2025TranscriptSlides
- May 2025Transcript
Credit ratings
- Rating update · 21 Jul from icra
- Rating update · 5 Jan from icra
- Rating update · 2 Jan from fitch
- Rating update · 6 Oct 2025 from fitch
- Rating update · 8 Jul 2025 from icra
- Rating update · 19 Mar 2025 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 24 Jan 2025 (unaudited). View the source filing. Figures are as filed and are not investment advice.
